Lifestyle treatments in cystic fibrosis: The NHS should pay

The NHS constitution for England. Updated 14 October 2015 www.gov.uk/government/publications/the-nhs-constitution-for-england. UK Cystic Fibrosis Registry, 2015 Sawicki, 2012, State of the Art-Managing treatment complexity in cystic fibrosis: Challenges and opportunities, Pediatr Pulmonol, 47, 523, 10.1002/ppul.22546 Sawicki, 2009, High treatment burden in adults with cystic fibrosis: Challenges to disease self-management, J Cyst Fibros, 8, 91, 10.1016/j.jcf.2008.09.007 Havermans, 2009, Health related quality of life in cystic fibrosis: To work or not to work?, J Cyst Fibros, 8, 218, 10.1016/j.jcf.2009.03.002 Quittner, 2014, Pulmonary medication adherence and health-care use in cystic fibrosis, Chest, 146, 142, 10.1378/chest.13-1926 Daniels, 2011, Accurate assessment of adherence. Self-report and clinician report vs electronic monitoring of nebulizers, Chest, 140, 425, 10.1378/chest.09-3074 Ball, 2013, Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week-days during school term-time, J Cyst Fibros, 12, 440, 10.1016/j.jcf.2012.12.012 Emerson, 2002, Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis, Pediatr Pulmonol, 34, 91, 10.1002/ppul.10127 Kerem, 2014, Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry, Eur Respir J, 43, 125, 10.1183/09031936.00166412 Harrison, 2014, Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF), J Cyst Fibros, 13, 692, 10.1016/j.jcf.2014.04.004 Ashish, 2012, Health-related quality of life in cystic fibrosis patients infected with transmissible pseudomonas aeruginosa strain: cohort study, J R Soc Med Sh Rep, 3, 12 National Institute for Health and Care Excellence, 2013 Harrison, 2014, Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF), J Cyst Fibros, 13, 692, 10.1016/j.jcf.2014.04.004 Bilton, 2014, An evaluation of treatment burden following initiation of TOBI Podhaler in patients with cystic fibrosis, J Cyst Fibros, 13, S65, 10.1016/S1569-1993(14)60210-1 NHS England clinical commissioning policy: Inhaled therapy for adults and children with cystic fibrosis Dec 2014: NHS England A01/P/b. www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/a01-policy-inhld-thrpy-cf.pdf. WHSSC Specialised services clinical access policy: Inhaled therapy of patients 6 years and older with cystic fibrosis May 2014: WHSSC CP74. www.wales.nhs.uk/sites3/documents/898/CP74%20inhaled%20therapy%20for%20patients%20with%20cystic%20fibrosis%2-v1%200.pdf. Blau, 2007, Microbial contamination of nebulisers in the home treatment of cystic fibrosis, Child Care Health Dev, 33, 491, 10.1111/j.1365-2214.2006.00669.x National Institute for Health and Care Excellence. Cystic fibrosis: diagnosis and management of cystic fibrosis. www.nice.org.uk/guidance/indevelopment/gid-cgwave0736.